Cat. #161206
MCF10A-PTENm-3 cell line
Cat. #: 161206
Sub-type: Continuous
Availability: 8-10 weeks
Organism: Human
Tissue: Mammarygland epithelium
Model: Mutant
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Medical-Industrial Translational Research Center
Institute: Fukushima Medical University
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: MCF10A-PTENm-3 cell line
- Alternate name: 06M17006
- Cancers detailed: Non-tumorigenic
- Research fields: Cancer;Cell biology
- Tool sub type: Continuous
- Parental cell: MCF10A, a non-tumorigenic cell line from human mammarygland epithelium
- Clone: PTEN_type-05
- Organism: Human
- Tissue: Mammarygland epithelium
- Morphology: Epithelial
- Growth properties: Adherent
- Model: Mutant
- Model description: Type-05; Type mutation: R233*; CDS mutation: c.697C>T; AA mutation: p.R233*; COSMIC Mutation ID: COSM5154
- Description: Non-tumorigenic immortalized breast epithelial cell stably overexpressing mutant cancer-related gene, PTEN (phosphatase and tensin homolog). PTEN is a multi-functional tumor suppressor that is mutated and lost in a large number of cancers at high frequency. Observed in prostate cancer, glioblastoma, endometrial, lung and breast cancer to varying degrees. Up to 70% of prostate cancer patients have been observed to have loss of expression of the gene. It is a part of the PI3K/AKT/mTOR pathway and mTOR inhibitors have been relatively ineffective in treating patients with PTEN loss.
- Application: Functional analysis of mutated genes, Drug screening
- Biosafety level: 1
Target Details
- Target: Phosphatase and tensin homolog [PTEN]
- Target background: Gene ID: 5728; References: DNA (mRNA): NM_000314.6; Protein: NP_000305.3
Applications
- Application: Functional analysis of mutated genes, Drug screening
Handling
- Format: Frozen
- Growth medium: DMEM/Ham's F-12 supplemented with 5% heat-inactivated horse serum, 10 Â?g/ml insulin (human, recombinant), 5 Â?M forskolin, 0.5 Â?g/ml hydrocortisone, 20 ng/ml EGF (human, recombinant), 100 U/ml penicillin, and 100 Â?g/ml streptomycin
- Temperature: 37° C
- Atmosphere: Humidified incubator with 5%Â CO2
- Shipping conditions: Dry ice
- Storage medium: CELLBANKER 2 (Zenogen pharma)
- Storage conditions: Liquid Nitrogen
- Initial handling information: Thaw the vial at 37 °C in a water bath?then seed cells into a T75 flask. Culture in a humidified Incubator at 37 ? with 5% CO2 in air. Culture medium should be changed every 2 to 3 days.
- Cultured in antibiotics: 100 U/ml Penicillin, and 100 Â?g/ml Streptomycin
- Mycoplasma free: Yes
- Characterisation tests: Comprehensive gene expression analysis; Identification of cell proliferation and cellular form; Drug sensitivity tests